entacapone vs Opicapone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: COMT · full Parkinson's Disease pipeline
entacapone · Comtess
Marketed by Orion Corporation and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT04246437 (registry estimate)
No aligned efficacy figure on record for this race.
Opicapone · Ongentys
Marketed by Amneal Pharmaceuticals and partners
NCT01568073 · Phase 3 · completed
BIPARK-1 was a randomized, double-blind, placebo- and entacapone-controlled Phase 3 trial in 600 patients with Parkinson disease and end-of-dose motor fluctuations. The primary endpoint was the change in absolute OFF-time, tested for each opicapone dose first for superiority to placebo and then for non-inferiority to entacapone. Opicapone 50 mg was superior to placebo (-60.8 minutes, p=0.0015) and non-inferior to entacapone. The 5 mg and 25 mg doses did not differ significantly from placebo. With one dose positive and two not, the result is mixed. Source: Ferreira et al., Lancet Neurol 2016.
Reported efficacy
Change from baseline (Visit 2) to the end of the double-blind period (Visit 9) in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III total score (Up to 24 weeks); Change from open-label baseline (Visit 9) to the end of the open-label period (Visit 15) in MDS-UPDRS Part IV total score. (Up to 1-year.): Change in MDS-UPDRS Part III total score from baseline to Week 24: -6.5 opicapone vs -4.3 placebo; difference -2.2 (95% CI -3.9, -0.5) favoring opicapone, p=0.010 (met)
Result source: NCT04978597
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | entacapone | Opicapone |
|---|---|---|
| OFF time, change | —Not posted · NCT00134966 | —Not posted · NCT04978597 |
| ON time without troublesome dyskinesia, change | —Not posted · NCT00134966 | —Not posted · NCT04978597 |
| UPDRS Part III, change | -3.7 vs -1.8vs Carbidopa/LevodopaNCT002192843 other results
| —Not posted · NCT04978597 |
| MDS-UPDRS Part II, change | —Not posted · NCT00134966 | —Not posted · NCT04978597 |
OFF time, change
- entacapone
- —Not posted · NCT00134966
- Opicapone
- —Not posted · NCT04978597
ON time without troublesome dyskinesia, change
- entacapone
- —Not posted · NCT00134966
- Opicapone
- —Not posted · NCT04978597
UPDRS Part III, change
- entacapone
- -3.7 vs -1.8vs Carbidopa/LevodopaNCT00219284
3 other results
- -3.6 vs -3.7 NCT00219284
- -3.6 vs -3.3 NCT00219284
- -4 vs -1.4 NCT00391898
- Opicapone
- —Not posted · NCT04978597
MDS-UPDRS Part II, change
- entacapone
- —Not posted · NCT00134966
- Opicapone
- —Not posted · NCT04978597
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. entacapone: 4 of 4 rows · Opicapone: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | entacapone | Opicapone |
|---|---|---|
| Dropout rate | 24.4%a NCT00219284 · Phase 4 · registry result, not featured evidence show 2 more results23.9% NCT00391898 · Phase 4 · registry result, not featured evidence — NCT01883505 · Phase 2 · registry result, not featured evidence · combination | 7.8%50 mgb NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3 show 57 more results9.2%25 mg NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3 9.8%5 mg NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3 16.9%50 mg NCT01227655 · Phase 3 · combination · Parkinson's Disease · phase 3 8.5%25 mg NCT01227655 · Phase 3 · combination · Parkinson's Disease · phase 3 17.2%50 mg NCT04986982 · Phase 4 · registry result, not featured evidence 10%5 mg NCT01568047 · Phase 2 · registry result, not featured evidence 10%30 mg NCT01568047 · Phase 2 · registry result, not featured evidence 10%15 mg NCT01568047 · Phase 2 · registry result, not featured evidence —50 mg NCT01568034 · Phase 2 · registry result, not featured evidence —25 mg NCT01568034 · Phase 2 · registry result, not featured evidence —100 mg NCT01568034 · Phase 2 · registry result, not featured evidence —Opicapone Alone NCT02305017 · Phase 1 · registry result, not featured evidence · monotherapy —Opicapone Plus Paracetamol NCT02305017 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT01520987 · Phase 1 · registry result, not featured evidence 0%50 mg NCT01520987 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01520987 · Phase 1 · registry result, not featured evidence 7.1%25 mg NCT01520987 · Phase 1 · registry result, not featured evidence 7.7%5 mg NCT01520987 · Phase 1 · registry result, not featured evidence 0%5 mg NCT01520987 · Phase 1 · registry result, not featured evidence 0% NCT02169427 · Phase 1 · registry result, not featured evidence — NCT01536366 · Phase 1 · registry result, not featured evidence · combination 0% NCT01515891 · Phase 1 · registry result, not featured evidence —BIA 9-1067 1h Before Rasagiline NCT01532141 · Phase 1 · registry result, not featured evidence · combination —BIA 9-1067 Alone NCT01532141 · Phase 1 · registry result, not featured evidence · monotherapy —BIA 9-1067 Concomitant Rasagiline NCT01532141 · Phase 1 · registry result, not featured evidence · combination —Rasagiline 1 h After BIA 9-1067 NCT01532128 · Phase 1 · registry result, not featured evidence · combination —Rasagiline Concomitant BIA 9-1067 NCT01532128 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02169414 · Phase 1 · registry result, not featured evidence 5.3%5 mg NCT02169414 · Phase 1 · registry result, not featured evidence 5.3%15 mg NCT02169414 · Phase 1 · registry result, not featured evidence —50 mg NCT01533077 · Phase 1 · registry result, not featured evidence —50 mg + 100/25 mg NCT01533077 · Phase 1 · registry result, not featured evidence · combination —50 mg + 100/25 mg NCT01533077 · Phase 1 · registry result, not featured evidence · combination — NCT02169440 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02169466 · Phase 1 · registry result, not featured evidence —25 mg NCT02169466 · Phase 1 · registry result, not featured evidence —100 mg NCT02169466 · Phase 1 · registry result, not featured evidence 0%50 mg NCT01520727 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01520727 · Phase 1 · registry result, not featured evidence 0%1200 mg NCT01520727 · Phase 1 · registry result, not featured evidence 0%800 mg NCT01520727 · Phase 1 · registry result, not featured evidence 0%400 mg NCT01520727 · Phase 1 · registry result, not featured evidence 0%200 mg NCT01520727 · Phase 1 · registry result, not featured evidence 0%100 mg NCT01520727 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01520727 · Phase 1 · registry result, not featured evidence —30 mg once daily NCT02092168 · Phase 1 · registry result, not featured evidence —30 mg once daily NCT02092168 · Phase 1 · registry result, not featured evidence —50 mg NCT02169479 · Phase 1 · registry result, not featured evidence —25 mg NCT02169479 · Phase 1 · registry result, not featured evidence —100 mg NCT02169479 · Phase 1 · registry result, not featured evidence —50 mg NCT02169895 · Phase 1 · registry result, not featured evidence —25 mg NCT02169895 · Phase 1 · registry result, not featured evidence —100 mg NCT02169895 · Phase 1 · registry result, not featured evidence 0%5 mg NCT02071810 · Phase 1 · registry result, not featured evidence 14.3%30 mg NCT02071810 · Phase 1 · registry result, not featured evidence 0%20 mg NCT02071810 · Phase 1 · registry result, not featured evidence 0%10 mg NCT02071810 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 14.4%a NCT00219284 · Phase 4 · registry result, not featured evidence show 2 more results6.5% NCT00391898 · Phase 4 · registry result, not featured evidence — NCT01883505 · Phase 2 · registry result, not featured evidence · combination | —50 mgb NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3 show 57 more results—25 mg NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3 —5 mg NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3 —50 mg NCT01227655 · Phase 3 · combination · Parkinson's Disease · phase 3 —25 mg NCT01227655 · Phase 3 · combination · Parkinson's Disease · phase 3 6.3%50 mg NCT04986982 · Phase 4 · registry result, not featured evidence 0%5 mg NCT01568047 · Phase 2 · registry result, not featured evidence 10%30 mg NCT01568047 · Phase 2 · registry result, not featured evidence 10%15 mg NCT01568047 · Phase 2 · registry result, not featured evidence —50 mg NCT01568034 · Phase 2 · registry result, not featured evidence —25 mg NCT01568034 · Phase 2 · registry result, not featured evidence —100 mg NCT01568034 · Phase 2 · registry result, not featured evidence —Opicapone Alone NCT02305017 · Phase 1 · registry result, not featured evidence · monotherapy —Opicapone Plus Paracetamol NCT02305017 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT01520987 · Phase 1 · registry result, not featured evidence —50 mg NCT01520987 · Phase 1 · registry result, not featured evidence —25 mg NCT01520987 · Phase 1 · registry result, not featured evidence —25 mg NCT01520987 · Phase 1 · registry result, not featured evidence —5 mg NCT01520987 · Phase 1 · registry result, not featured evidence —5 mg NCT01520987 · Phase 1 · registry result, not featured evidence — NCT02169427 · Phase 1 · registry result, not featured evidence — NCT01536366 · Phase 1 · registry result, not featured evidence · combination — NCT01515891 · Phase 1 · registry result, not featured evidence —BIA 9-1067 1h Before Rasagiline NCT01532141 · Phase 1 · registry result, not featured evidence · combination —BIA 9-1067 Alone NCT01532141 · Phase 1 · registry result, not featured evidence · monotherapy —BIA 9-1067 Concomitant Rasagiline NCT01532141 · Phase 1 · registry result, not featured evidence · combination —Rasagiline 1 h After BIA 9-1067 NCT01532128 · Phase 1 · registry result, not featured evidence · combination —Rasagiline Concomitant BIA 9-1067 NCT01532128 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02169414 · Phase 1 · registry result, not featured evidence 0%5 mg NCT02169414 · Phase 1 · registry result, not featured evidence 5.3%15 mg NCT02169414 · Phase 1 · registry result, not featured evidence —50 mg NCT01533077 · Phase 1 · registry result, not featured evidence —50 mg + 100/25 mg NCT01533077 · Phase 1 · registry result, not featured evidence · combination —50 mg + 100/25 mg NCT01533077 · Phase 1 · registry result, not featured evidence · combination — NCT02169440 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02169466 · Phase 1 · registry result, not featured evidence —25 mg NCT02169466 · Phase 1 · registry result, not featured evidence —100 mg NCT02169466 · Phase 1 · registry result, not featured evidence —50 mg NCT01520727 · Phase 1 · registry result, not featured evidence —25 mg NCT01520727 · Phase 1 · registry result, not featured evidence —1200 mg NCT01520727 · Phase 1 · registry result, not featured evidence —800 mg NCT01520727 · Phase 1 · registry result, not featured evidence —400 mg NCT01520727 · Phase 1 · registry result, not featured evidence —200 mg NCT01520727 · Phase 1 · registry result, not featured evidence —100 mg NCT01520727 · Phase 1 · registry result, not featured evidence —10 mg NCT01520727 · Phase 1 · registry result, not featured evidence —30 mg once daily NCT02092168 · Phase 1 · registry result, not featured evidence —30 mg once daily NCT02092168 · Phase 1 · registry result, not featured evidence —50 mg NCT02169479 · Phase 1 · registry result, not featured evidence —25 mg NCT02169479 · Phase 1 · registry result, not featured evidence —100 mg NCT02169479 · Phase 1 · registry result, not featured evidence —50 mg NCT02169895 · Phase 1 · registry result, not featured evidence —25 mg NCT02169895 · Phase 1 · registry result, not featured evidence —100 mg NCT02169895 · Phase 1 · registry result, not featured evidence —5 mg NCT02071810 · Phase 1 · registry result, not featured evidence —30 mg NCT02071810 · Phase 1 · registry result, not featured evidence —20 mg NCT02071810 · Phase 1 · registry result, not featured evidence —10 mg NCT02071810 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 4.4%a NCT00219284 · Phase 4 · registry result, not featured evidence show 2 more results2.2% NCT00391898 · Phase 4 · registry result, not featured evidence 0% NCT01883505 · Phase 2 · registry result, not featured evidence · combination | 3.5%50 mgb NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3 show 57 more results0.8%25 mg NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3 3.3%5 mg NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3 6%50 mg NCT01227655 · Phase 3 · combination · Parkinson's Disease · phase 3 3.2%25 mg NCT01227655 · Phase 3 · combination · Parkinson's Disease · phase 3 6.3%50 mg NCT04986982 · Phase 4 · registry result, not featured evidence 0%5 mg NCT01568047 · Phase 2 · registry result, not featured evidence 0%30 mg NCT01568047 · Phase 2 · registry result, not featured evidence 0%15 mg NCT01568047 · Phase 2 · registry result, not featured evidence 0%50 mg NCT01568034 · Phase 2 · registry result, not featured evidence 0%25 mg NCT01568034 · Phase 2 · registry result, not featured evidence 0%100 mg NCT01568034 · Phase 2 · registry result, not featured evidence 0%Opicapone Alone NCT02305017 · Phase 1 · registry result, not featured evidence · monotherapy 0%Opicapone Plus Paracetamol NCT02305017 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT01520987 · Phase 1 · registry result, not featured evidence 0%50 mg NCT01520987 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01520987 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01520987 · Phase 1 · registry result, not featured evidence 0%5 mg NCT01520987 · Phase 1 · registry result, not featured evidence 0%5 mg NCT01520987 · Phase 1 · registry result, not featured evidence 0% NCT02169427 · Phase 1 · registry result, not featured evidence 0% NCT01536366 · Phase 1 · registry result, not featured evidence · combination 0% NCT01515891 · Phase 1 · registry result, not featured evidence 0%BIA 9-1067 1h Before Rasagiline NCT01532141 · Phase 1 · registry result, not featured evidence · combination 0%BIA 9-1067 Alone NCT01532141 · Phase 1 · registry result, not featured evidence · monotherapy 0%BIA 9-1067 Concomitant Rasagiline NCT01532141 · Phase 1 · registry result, not featured evidence · combination 0%Rasagiline 1 h After BIA 9-1067 NCT01532128 · Phase 1 · registry result, not featured evidence · combination 0%Rasagiline Concomitant BIA 9-1067 NCT01532128 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02169414 · Phase 1 · registry result, not featured evidence 0%5 mg NCT02169414 · Phase 1 · registry result, not featured evidence 0%15 mg NCT02169414 · Phase 1 · registry result, not featured evidence 0%50 mg NCT01533077 · Phase 1 · registry result, not featured evidence 0%50 mg + 100/25 mg NCT01533077 · Phase 1 · registry result, not featured evidence · combination 0%50 mg + 100/25 mg NCT01533077 · Phase 1 · registry result, not featured evidence · combination 0% NCT02169440 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02169466 · Phase 1 · registry result, not featured evidence 0%25 mg NCT02169466 · Phase 1 · registry result, not featured evidence 0%100 mg NCT02169466 · Phase 1 · registry result, not featured evidence 0%50 mg NCT01520727 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01520727 · Phase 1 · registry result, not featured evidence 0%1200 mg NCT01520727 · Phase 1 · registry result, not featured evidence 0%800 mg NCT01520727 · Phase 1 · registry result, not featured evidence 0%400 mg NCT01520727 · Phase 1 · registry result, not featured evidence 0%200 mg NCT01520727 · Phase 1 · registry result, not featured evidence 0%100 mg NCT01520727 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01520727 · Phase 1 · registry result, not featured evidence 0%30 mg once daily NCT02092168 · Phase 1 · registry result, not featured evidence 0%30 mg once daily NCT02092168 · Phase 1 · registry result, not featured evidence 0%50 mg NCT02169479 · Phase 1 · registry result, not featured evidence 0%25 mg NCT02169479 · Phase 1 · registry result, not featured evidence 0%100 mg NCT02169479 · Phase 1 · registry result, not featured evidence 0%50 mg NCT02169895 · Phase 1 · registry result, not featured evidence 0%25 mg NCT02169895 · Phase 1 · registry result, not featured evidence 0%100 mg NCT02169895 · Phase 1 · registry result, not featured evidence 0%5 mg NCT02071810 · Phase 1 · registry result, not featured evidence 0%30 mg NCT02071810 · Phase 1 · registry result, not featured evidence 0%20 mg NCT02071810 · Phase 1 · registry result, not featured evidence 0%10 mg NCT02071810 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | a nausea 17.2% diarrhoea 16.1% dizziness 8.9% NCT00219284 · Phase 4 · registry result, not featured evidence show 2 more resultsdyskinesia 15.6% anxiety 11.1% retching 6.7% NCT00391898 · Phase 4 · registry result, not featured evidence back pain 12.5% (placebo 0%) pain in extremity 12.5% (placebo 9.1%) abdominal pain lower 0% (placebo 0%) NCT01883505 · Phase 2 · registry result, not featured evidence · combination | 50 mgb dyskinesia 15.7% (placebo 4.1%) constipation 6.1% (placebo 2.5%) insomnia 6.1% (placebo 0.8%) NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3 show 57 more results25 mg dyskinesia 7.6% (placebo 4.1%) insomnia 5.9% (placebo 0.8%) dizziness 5% (placebo 0.8%) NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3 5 mg dyskinesia 13.9% (placebo 4.1%) back pain 3.3% (placebo 5%) constipation 3.3% (placebo 2.5%) NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3 50 mg dyskinesia 24% (placebo 8.1%) blood cpk increased 8% (placebo 3.7%) constipation 6.7% (placebo 1.5%) NCT01227655 · Phase 3 · combination · Parkinson's Disease · phase 3 25 mg dyskinesia 24% (placebo 8.1%) dry mouth 10.4% (placebo 0.7%) constipation 9.6% (placebo 1.5%) NCT01227655 · Phase 3 · combination · Parkinson's Disease · phase 3 50 mg nausea 10.9% (placebo 7.9%) anxiety 9.4% (placebo 3.2%) constipation 7.8% (placebo 1.6%) NCT04986982 · Phase 4 · registry result, not featured evidence 5 mg dizziness 10% (placebo 10%) fatigue 10% (placebo 0%) hyperhidrosis 10% (placebo 0%) NCT01568047 · Phase 2 · registry result, not featured evidence 30 mg abdominal pain upper 10% (placebo 0%) diarrhoea 10% (placebo 0%) dyskinesia 10% (placebo 0%) NCT01568047 · Phase 2 · registry result, not featured evidence 15 mg bradyphrenia 10% (placebo 0%) depression 10% (placebo 0%) dizziness 10% (placebo 10%) NCT01568047 · Phase 2 · registry result, not featured evidence 50 mg blood pressure increased 10% (placebo 0%) eosinophil percentage increased 10% (placebo 11.1%) hypertension 10% (placebo 0%) NCT01568034 · Phase 2 · registry result, not featured evidence 25 mg anaemia 10% (placebo 0%) constipation 10% (placebo 0%) headache 10% (placebo 0%) NCT01568034 · Phase 2 · registry result, not featured evidence 100 mg eosinophil percentage increased 10% (placebo 11.1%) haematuria 10% (placebo 0%) hypertension 10% (placebo 0%) NCT01568034 · Phase 2 · registry result, not featured evidence tooth abscess 3.6% nasopharyngitis 0% NCT02305017 · Phase 1 · registry result, not featured evidence · monotherapy nasopharyngitis 3.6% tooth abscess 0% NCT02305017 · Phase 1 · registry result, not featured evidence · combination 50 mg arthropod bite 9.1% (placebo 6.7%) back pain 9.1% (placebo 0%) dizziness 9.1% (placebo 6.7%) NCT01520987 · Phase 1 · registry result, not featured evidence 50 mg vessel puncture site haematoma 25% (placebo 13.3%) tension headache 16.7% (placebo 0%) back pain 8.3% (placebo 0%) NCT01520987 · Phase 1 · registry result, not featured evidence 25 mg vessel puncture site haematoma 25% (placebo 13.3%) hordeolum 8.3% (placebo 6.7%) myalgia 8.3% (placebo 0%) NCT01520987 · Phase 1 · registry result, not featured evidence 25 mg vessel puncture site haematoma 14.3% (placebo 13.3%) dizziness postural 7.1% (placebo 0%) energy increased 7.1% (placebo 0%) NCT01520987 · Phase 1 · registry result, not featured evidence 5 mg vessel puncture site haematoma 30.8% (placebo 13.3%) nausea 23.1% (placebo 6.7%) dizziness 7.7% (placebo 6.7%) NCT01520987 · Phase 1 · registry result, not featured evidence 5 mg headache 14.3% (placebo 6.7%) arthropod bite 7.1% (placebo 6.7%) contusion 7.1% (placebo 0%) NCT01520987 · Phase 1 · registry result, not featured evidence somnolence 33.3% frequent bowel movements 16.7% headache 16.7% NCT02169427 · Phase 1 · registry result, not featured evidence alanine aminotransferase increased 4.2% aspartate aminotransferase increased 4.2% fall 4.2% NCT01536366 · Phase 1 · registry result, not featured evidence · combination headache 50% tiredness 50% flatulence 25% NCT01515891 · Phase 1 · registry result, not featured evidence nasopharyngitis 8.3% back pain 4.2% headache 4.2% NCT01532141 · Phase 1 · registry result, not featured evidence · combination headache 24% bronchitis 4% chest discomfort 4% NCT01532141 · Phase 1 · registry result, not featured evidence · monotherapy headache 4.2% nasopharyngitis 4.2% neck pain 4.2% NCT01532141 · Phase 1 · registry result, not featured evidence · combination blood creatine phosphokinase increased 4.2% headache 4.2% sciatica 4.2% NCT01532128 · Phase 1 · registry result, not featured evidence · combination diarrhoea 4.2% influenza like illness 4.2% sciatica 4.2% NCT01532128 · Phase 1 · registry result, not featured evidence · combination 50 mg asthenia 5.6% (placebo 0%) dizziness 5.6% (placebo 0%) headache 5.6% (placebo 5.6%) NCT02169414 · Phase 1 · registry result, not featured evidence 5 mg headache 26.3% (placebo 5.6%) diarrhoea 10.5% (placebo 0%) arthralgia 5.3% (placebo 0%) NCT02169414 · Phase 1 · registry result, not featured evidence 15 mg nausea 21.1% (placebo 0%) back pain 5.3% (placebo 0%) cystitis 5.3% (placebo 0%) NCT02169414 · Phase 1 · registry result, not featured evidence 50 mg somnolence 33.3% headache 11.1% blood pressure systolic increased 5.6% NCT01533077 · Phase 1 · registry result, not featured evidence 50 mg + 100/25 mg headache 25% somnolence 25% oropharyngeal pain 12.5% NCT01533077 · Phase 1 · registry result, not featured evidence · combination 50 mg + 100/25 mg somnolence 22.2% headache 16.7% rash 11.1% NCT01533077 · Phase 1 · registry result, not featured evidence · combination blood creatine phosphokinase increased 10% decreased appetite 5% dizziness 5% NCT02169440 · Phase 1 · registry result, not featured evidence · combination 50 mg blood creatine phosphokinase increased 9.1% (placebo 0%) nasopharyngitis 4.5% (placebo 0%) oral herpes 4.5% (placebo 0%) NCT02169466 · Phase 1 · registry result, not featured evidence 25 mg blood creatine phosphokinase increased 4.8% (placebo 0%) respiratory tract infection 4.8% (placebo 0%) depression 0% (placebo 4.8%) NCT02169466 · Phase 1 · registry result, not featured evidence 100 mg headache 4.5% (placebo 4.8%) rash 4.5% (placebo 0%) rhinorrhea 4.5% (placebo 0%) NCT02169466 · Phase 1 · registry result, not featured evidence 50 mg nasopharyngitis 16.7% (placebo 0%) syncope vasovagal 16.7% (placebo 0%) epistaxis 0% (placebo 0%) NCT01520727 · Phase 1 · registry result, not featured evidence 25 mg epistaxis 0% (placebo 0%) gastroenteritis 0% (placebo 6.3%) headache 0% (placebo 0%) NCT01520727 · Phase 1 · registry result, not featured evidence 1200 mg headache 16.7% (placebo 0%) epistaxis 0% (placebo 0%) gastroenteritis 0% (placebo 6.3%) NCT01520727 · Phase 1 · registry result, not featured evidence 800 mg epistaxis 0% (placebo 0%) gastroenteritis 0% (placebo 6.3%) headache 0% (placebo 0%) NCT01520727 · Phase 1 · registry result, not featured evidence 400 mg epistaxis 16.7% (placebo 0%) gastroenteritis 0% (placebo 6.3%) headache 0% (placebo 0%) NCT01520727 · Phase 1 · registry result, not featured evidence 200 mg headache 16.7% (placebo 0%) epistaxis 0% (placebo 0%) gastroenteritis 0% (placebo 6.3%) NCT01520727 · Phase 1 · registry result, not featured evidence 100 mg epistaxis 0% (placebo 0%) gastroenteritis 0% (placebo 6.3%) headache 0% (placebo 0%) NCT01520727 · Phase 1 · registry result, not featured evidence 10 mg epistaxis 0% (placebo 0%) gastroenteritis 0% (placebo 6.3%) headache 0% (placebo 0%) NCT01520727 · Phase 1 · registry result, not featured evidence 30 mg once daily headache 8.3% pharyngolaryngeal pain 8.3% bronchitis lymphangitis 0% NCT02092168 · Phase 1 · registry result, not featured evidence 30 mg once daily bronchitis lymphangitis 8.3% influenza like illness 8.3% pruritus 8.3% NCT02092168 · Phase 1 · registry result, not featured evidence 50 mg dizziness 18.8% (placebo 0%) headache 12.5% (placebo 0%) somnolence 12.5% (placebo 7.1%) NCT02169479 · Phase 1 · registry result, not featured evidence 25 mg somnolence 20% (placebo 7.1%) headache 13.3% (placebo 0%) nausea 13.3% (placebo 0%) NCT02169479 · Phase 1 · registry result, not featured evidence 100 mg blood creatine phosphokinase increased 13.3% (placebo 0%) groin pain 6.7% (placebo 0%) hematuria 6.7% (placebo 0%) NCT02169479 · Phase 1 · registry result, not featured evidence 50 mg somnolence 31.3% (placebo 12.5%) insomnia 12.5% (placebo 0%) nausea 12.5% (placebo 6.3%) NCT02169895 · Phase 1 · registry result, not featured evidence 25 mg ocular hyperaemia 18.8% (placebo 6.3%) somnolence 18.8% (placebo 12.5%) headache 12.5% (placebo 0%) NCT02169895 · Phase 1 · registry result, not featured evidence 100 mg somnolence 35.7% (placebo 12.5%) cough 7.1% (placebo 6.3%) dry mouth 7.1% (placebo 0%) NCT02169895 · Phase 1 · registry result, not featured evidence 5 mg headache 50% (placebo 0%) muscle spasms 0% (placebo 0%) orthostatic hypotension 0% (placebo 0%) NCT02071810 · Phase 1 · registry result, not featured evidence 30 mg headache 14.3% (placebo 0%) muscle spasms 14.3% (placebo 0%) vomiting 14.3% (placebo 0%) NCT02071810 · Phase 1 · registry result, not featured evidence 20 mg orthostatic hypotension 16.7% (placebo 0%) headache 0% (placebo 0%) muscle spasms 0% (placebo 0%) NCT02071810 · Phase 1 · registry result, not featured evidence 10 mg vomiting 16.7% (placebo 0%) headache 0% (placebo 0%) muscle spasms 0% (placebo 0%) NCT02071810 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 53 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
entacapone
show 3 more results
show 2 more results
show 3 more results
Opicapone
show 4 more results
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: entacapone's landscape · Opicapone's landscape